Chimeric Peptide-Engineered Polyprodrug Enhances Cytotoxic T Cell Response by Inducing Immunogenic Cell Death and Upregulating Major Histocompatibility Complex Class I DOI
Ying Chen, Yi Cen,

Xin-Xuan Li

et al.

ACS Nano, Journal Year: 2024, Volume and Issue: 19(1), P. 837 - 851

Published: Dec. 28, 2024

Tumor-specific cytotoxic T cell immunity is critically dependent on effective antigen presentation and sustained signal transduction. However, this immune response frequently compromised by the inherently low immunogenicity of breast cancer deficiency in major histocompatibility complex class I (MHC-I) expression. Herein, a chimeric peptide-engineered stoichiometric polyprodrug (PDPP) fabricated to potentiate response, characterized high drug loading capacity precise ratio, which immunogenic death (ICD) inducer protoporphyrin IX (PpIX) epigenetic decitabine (DAC) are condensed into called PpIX-DAC. Furthermore, programmed ligand 1 (PD-L1) targeting peptide sequence (CVRARTR) conjugated onto DSPE-PEG2000-Mal for encapsulation PpIX-DAC, thereby enhancing cancer-targeted delivery. PDPP exerts its antitumor effects through photodynamic therapy (PDT), ablating cells while concurrently inducing release damage-associated molecular patterns (DAMPs) boost tumor immunogenicity. Additionally, can upregulate MHC-I expression via modulation, synergistically augmenting together with PD-L1 blockade. In short, induces robust immunity, causing eradication primary metastatic cancer. This study may inspire development nanomedicine clinical translation.

Language: Английский

Triggering immunogenic death of cancer cells by nanoparticles overcomes immunotherapy resistance DOI
Ting Mei, Ting Ye,

Donghua Huang

et al.

Cellular Oncology, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 20, 2024

Language: Английский

Citations

0
Chimeric Peptide-Engineered Polyprodrug Enhances Cytotoxic T Cell Response by Inducing Immunogenic Cell Death and Upregulating Major Histocompatibility Complex Class I DOI
Ying Chen, Yi Cen,

Xin-Xuan Li

et al.

ACS Nano, Journal Year: 2024, Volume and Issue: 19(1), P. 837 - 851

Published: Dec. 28, 2024

Tumor-specific cytotoxic T cell immunity is critically dependent on effective antigen presentation and sustained signal transduction. However, this immune response frequently compromised by the inherently low immunogenicity of breast cancer deficiency in major histocompatibility complex class I (MHC-I) expression. Herein, a chimeric peptide-engineered stoichiometric polyprodrug (PDPP) fabricated to potentiate response, characterized high drug loading capacity precise ratio, which immunogenic death (ICD) inducer protoporphyrin IX (PpIX) epigenetic decitabine (DAC) are condensed into called PpIX-DAC. Furthermore, programmed ligand 1 (PD-L1) targeting peptide sequence (CVRARTR) conjugated onto DSPE-PEG2000-Mal for encapsulation PpIX-DAC, thereby enhancing cancer-targeted delivery. PDPP exerts its antitumor effects through photodynamic therapy (PDT), ablating cells while concurrently inducing release damage-associated molecular patterns (DAMPs) boost tumor immunogenicity. Additionally, can upregulate MHC-I expression via modulation, synergistically augmenting together with PD-L1 blockade. In short, induces robust immunity, causing eradication primary metastatic cancer. This study may inspire development nanomedicine clinical translation.

Language: Английский

Citations

0